Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human gut metagenome

ABSTRACT: Metagenome from fecal samples collect from healty human subject during probiotic intervention trial

PROVIDER: PRJNA306016 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR3030540.fastq.gz	Fastqsanger.gz
	SRR3030550.fastq.gz	Fastqsanger.gz
	SRR3030560.fastq.gz	Fastqsanger.gz
	SRR3030570.fastq.gz	Fastqsanger.gz
	SRR3030580.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 118

Similar Datasets

Gut microbiota composition after 12 weeks of home based lifestyle intervention in breast cancer survivors (MOVIS)

Project description:Analysis of breast cancer survivors' gut microbiota after lifestyle intervention, during the COVID-19 lockdown, by 16S sequencing of fecal samples.

2023-01-13 | E-MTAB-12486 | biostudies-arrayexpress

Analysis of the relationship between the Gut Microbiota Enterotypes and colorectal adenoma

Project description:Collect fecal samples for Acer sequencing

| PRJEB58040 | ENA

Shotgun metagenomic profiling of human fecal microbiota before and after aerobic exercise intervention

Project description:Lean nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as a distinct clinical phenotype with limited evidence for effective non-pharmacological interventions and unclear mechanistic pathways. Aerobic exercise is recommended for NAFLD management; however, its effects and the gut microbiota–associated mechanisms in lean NAFLD remain incompletely understood. This dataset was generated from a randomized controlled trial (ClinicalTrials.gov identifier: NCT04882644). Participants assigned to the aerobic exercise intervention group provided fecal samples at baseline and after the 3-month intervention. A total of 33 paired fecal samples were included in this dataset. Gut microbiota profiles were generated using shotgun metagenomic sequencing. The dataset includes processed and de-identified species-level relative abundance tables derived from fecal samples collected before and after the intervention. These data were used to characterize exercise-induced alterations in gut microbial composition and interindividual variability in microbiota responses to aerobic exercise in lean NAFLD. The data support integrative analyses with clinical phenotypes and circulating metabolomic profiles to explore gut microbiota–associated mechanisms underlying the metabolic benefits of aerobic exercise.

2025-12-23 | GSE314617 | GEO

16S rRNA gene sequencing of human fecal microbiota before and after exercise intervention

Project description:Lean nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as a distinct clinical phenotype with limited evidence for effective non-pharmacological interventions and unclear mechanistic pathways. Aerobic exercise is recommended for NAFLD management, yet its effects and underlying gut microbiota–mediated mechanisms in lean NAFLD remain insufficiently characterized. This study is based on a randomized controlled trial (ClinicalTrials.gov identifier: NCT04882644) in which 100 adults with lean NAFLD were randomly assigned to a 3-month aerobic exercise intervention or usual care. 63 paired fecal samples were collected at baseline and after intervention. Gut microbiota profiles were generated using 16S rRNA gene sequencing. The dataset includes processed taxonomic abundance tables derived from fecal samples collected before and after the intervention. These data were used to characterize exercise-induced alterations in gut microbial diversity, composition, and functional potential, and to explore interindividual heterogeneity in microbiota responses to aerobic exercise in lean NAFLD. The microbiome data deposited in this series support integrative analyses with clinical phenotypes and circulating metabolomic profiles, aiming to elucidate gut microbiota–associated mechanisms underlying the metabolic benefits of aerobic exercise in lean NAFLD.

2025-12-18 | GSE314066 | GEO

The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. (COPRO-Seq)

Project description:Understanding how the human gut microbiota and host are impacted by probiotic bacterial strains requires carefully controlled studies in humans, and in mouse models of the gut ecosystem where potentially confounding variables that are difficult to control in humans can be constrained. Therefore, we characterized the fecal microbiomes and metatranscriptomes of adult female monozygotic twin pairs through repeated sampling 4 weeks prior to, 7 weeks during, and 4 weeks following consumption of a commercially-available fermented milk product (FMP) containing a consortium of Bifidobacterium animalis subsp. lactis, two strains of Lactobacillus delbrueckii subsp. bulgaricus, Lactococcus lactis subsp. cremoris, and Streptococcus thermophilus. In addition, gnotobiotic mice harboring a 15-species model human gut microbiota whose genomes contain 58,399 known or predicted protein-coding genes were studied prior to and after gavage with all five sequenced FMP strains. 140 samples total. Evaluation of changes in a model community's structure over time after exposure to a consortium of 5 fermented milk product (FMP) strains.

2011-11-01 | E-GEOD-31943 | biostudies-arrayexpress

Metaproteomic study about diet-induced effects on the gut microbiota of patients affected by Crohn's disease

Project description:Metaproteomic study on fecal samples collected from Crohn's Disease (CD) patients and some Household Healthy Controls (HHC) during an eight week Lof Fat/High fiber diet intervention. Stoo sampling was performed at baseline (V1), week 8 (V2) and week 36 (V3). Protein Identification and quantitation was performed by MetaLab 2.3 (MaxQuant).

2024-02-01 | MSV000093975 | MassIVE

Effects of a Probiotic Formulation Based on SF68, Phytosterols, and 6S-5-Methyltetrahydrofolic Acid on Body Composition, Biochemical Parameters, Gut Microbiota, and Gastrointestinal and General Symptoms of Overweight/Obese Subjects: The PrObesity Study

Project description:Obesity and dyslipidemia are increasingly widespread. Considering gut microbiota's (GM) role in energy balance, probiotics represent a promising non-pharmacological approach. This study assessed a probiotic formulation (SF68 + phytosterols + (6S)-5-methyltetrahydrofolic acid) on anthropometric, biochemical, and GM parameters, as well as gastrointestinal and general symptoms, in overweight/obese individuals with low-to-moderate cardiovascular risk. Forty participants (30F, mean age 51.5 ± 11 years) were randomized to receive either the probiotic or placebo daily for 12 weeks. Anthropometric data, questionnaires, and biological samples were collected pre- and post-intervention. While both groups showed significant (p < 0.05) improvements, the probiotic group showed greater reductions in waist circumference (−1.8 cm), fat mass (−1.8 kg; −1.7%), total cholesterol (−11 mg/dL), and LDL-cholesterol (−10.3 mg/dL), along with an increased HDL/LDL ratio (+0.1). Both probiotic and placebo resulted in a significant reduction in HbA1c (−1.7 mmol/mol and −1.5 mmol/mol, respectively). The probiotic formulation also reduced erythrocyte ROS (−29.7%), granulocyte ROS (−28.4%), and plasma nitrite/nitrate (49.5%) and significantly increased erythrocyte glutathione (GSH; +81.9%). Gastrointestinal symptoms improved, and GM analysis showed an increased Evenness index and reduced Lachnospirales abundance after probiotic treatment. These findings suggest the multi-component probiotic formulation may support metabolic and gut health in overweight or obese individuals, although further research is warranted

2025-09-19 | GSE295639 | GEO

Functional Dynamics of the Elderly Gut Microbiome During Probiotic Consumption

Project description:<p>A mechanistic understanding of the health benefits conferred by consumption of probiotic bacteria has been limited by our knowledge of the resident gut microbiota and its interaction with the host. We used fecal samples from a study of twelve healthy individuals aged 65-80 to characterize the structure and functional dynamics of the gut microbiota associated with consumption of the single-organism probiotic, Lactobacillus rhamnosus GG ATCC 53103 (LGG). Samples were collected prior to probiotic consumption (day 0), on day 28 immediately after consuming 10^10 CFU of LGG twice daily for 28 days and day 56, one month after stopping LGG consumption. Our integrative approach incorporated bacterial 16S rRNA gene sequencing, whole-community expression profiling using RNA-seq, and metagenomic sequencing. We highlight the value of combinatorial 'omics methods and concomitant high-resolution informatics to probe the role that probiotics may play on the structure and function of the resident microbiota.</p>

| phs000896 | dbGaP

Project description:Probiotic intervention during ship voyage to Antarctica

| PRJNA694018 | ENA

Gut microbiota analysis after 3months probiotic-like bacteria or placebo treatment in subjects with metabolic syndrome

Project description:Background: Probiotic-like bacteria treatment has been described to be associated with gut microbiota modifications. Goal: To decipher if the effects of the tested probiotic-like bacteria are due to the bacteria itself or due to the effects of the bacteria on the gut microbiota. Methodology: In this study, gut microbiota has been analyzed from feces samples of subjects with metabolic syndrome and treated with one of the 2 tested probiotic-like bacteria or with the placebo during 3months.

| EGAS00001003585 | EGA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data